Biogen (BIIB) Upgraded to Buy with Price Target Raised to $235

Biogen (BIIB) Stock Jumps on Analyst Upgrade Before Key Alzheimer’s Data Release

Truist upgrades Biogen (BIIB) stock to Buy with $235 target ahead of Alzheimer's drug data. Shares rise 1.3% premarket on positive analyst o

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

This could be a key move for future growth.

Biogena Group Invest Aktie: 25 Millionen für Direct-Market-Plus

Biogena Group Invest bereitet den Sprung in den Direct Market Plus vor. Der Salzburger Mikronährstoff-Spezialist setzt dabei auf eine deutli

Syngenis banks $4M pre-float to power AI-driven biotech platform

Perth biotech Syngenis Labs has banked an oversubscribed $4M pre-IPO raise to expand its AI-powered RNA platform and strengthen domestic gen

Biogen's Q2 2026 Earnings: What to Expect

Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal

Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy